Scholars Central

EditorialPublished 29 Jul 2025

Immune Checkpoints: Targets, Resistance, and Future Therapies

Authors: Dr. Pablo Ruiz

Department of Immunology UNAM, México

Immunology: Current Research

Volume 9 · Issue 4 · Pages 1–3

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Immune checkpoint inhibitors targeting pathways like PD-1/PD-L1 and CTLA-4 have revolutionized cancer immunotherapy.These pathways regulate T cell responses, and their blockade can restore anti-tumor immunity. Challenges include tumor microenvironment modulation, resistance mechanisms, and the need for better predictive biomarkers. Emerging checkpoints and the interplayof innate and adaptive immunity, cellular metabolism, and the gut microbiome are critical areas of investigation for optimizingtherapeutic efficacy.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Immunology: Current Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalImmunology: Current Research
  • SubjectImmunology & Microbiology
  • BylineArticles whose byline prints “Dr. Pablo Ruiz”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels